Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
R-CHOP is a combination chemotherapy regimen consisting of five drugs: cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), vincristine (a vinca alkaloid), prednisone (a corticosteroid), and rituximab (a monoclonal antibody targeting CD20). This regimen is primarily used as first-line therapy for B-cell non-Hodgkin lymphomas such as diffuse large B-cell lymphoma (DLBCL) and advanced follicular lymphoma. Each component acts via a different mechanism to kill cancer cells or modulate the immune response. Cyclophosphamide crosslinks DNA leading to cell death; doxorubicin intercalates DNA and inhibits topoisomerase II; vincristine disrupts microtubule formation inhibiting mitosis; prednisone induces apoptosis in certain cancerous lymphocytes by modulating gene expression through the glucocorticoid receptor; rituximab binds CD20 on B-cells leading to their destruction via immune-mediated mechanisms[2][3][7].
- Brand names
- R-CHOP
- Other names
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneR CHOPRituximab CHOP regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab.